drugset / Trial / NCT04452929
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
RandomizedParallel-groupDouble-blindHealth-services research
Summary
A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in humans. Followed by a 6-month open-label extension.
Timeline
- Start
- 2020-07-22
- Primary completion
- 2022-02
- Completion
- 2022-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcitonin Gene-Related Peptide | Peptide | 1.5 ug | Intravenous |
| Comparator | Cilostazol | Small molecule | 200 mg | Oral |
| Subject | Erenumab | Monoclonal antibody | 140 mg | Subcutaneous |